SGMT

Over the past six months, Sagimet Biosciences' stock has been influenced by several events. These include insider selling in November 2025, participation in healthcare conferences, and the release of Fourth Quarter and Full Year 2025 financial results in March 2026. In April 2026, Andreas Grauer was appointed as the new Chief Medical Officer, and the company announced plans for a U.S. Phase 3 clinical trial of oral denifanstat for moderate to severe acne. Sagimet also announced the pricing of a $175.0 million underwritten offering of Series A Common Stock. As of May 2026, the stock price was $7.64, with analysts maintaining a "Moderate Buy" consensus rating.